¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀå
Patient Blood Management
»óǰÄÚµå : 1594912
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 93 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº 2030³â±îÁö 236¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 152¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº 2023-2030³â CAGR 6.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 236¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ±â±â´Â CAGR 6.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 101¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ã¾à¡¤Å°Æ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 7.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 40¾ï ´Þ·¯, Áß±¹Àº CAGR 9.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº 2023³â¿¡ 40¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 9.8%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð°¡ 56¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.3%¿Í 5.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö´ë ÇコÄɾ¼­ ȯÀÚ Ç÷¾× °ü¸®°¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â?

ȯÀÚ Ç÷¾× °ü¸®(PBM)´Â ¼öÇ÷ÀÌ ÇÊ¿äÇÑ È¯ÀÚÀÇ Ä¡·á¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ Ã¼°èÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÔÀ¸·Î½á Çö´ë ÀÇ·á¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ¾ÒÀ¸¸ç, ºóÇ÷À» °ü¸®ÇÏ°í ¼ö¼ú Áß ÃâÇ÷À» ÁÙÀ̸ç ȯÀÚÀÇ ÀûÇ÷±¸ ¼öÄ¡¸¦ ÃÖÀûÈ­ÇÏ¿© ¼öÇ÷ÀÇ Çʿ伺À» ÃÖ¼ÒÈ­ÇÏ°í °¨¿°, ¸é¿ª ¹ÝÀÀ, ¼öÇ÷ °ü·Ã ÇÕº´Áõ µî ¼öÇ÷°ú °ü·ÃµÈ À§ÇèÀ» ÁÙÀÓÀ¸·Î½á ȯÀÚÀÇ ¾ÈÀü°ú ÀÓ»ó °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. PBMÀÇ Á߿伺Àº °¨¿°, ¸é¿ª ¹ÝÀÀ, ¼öÇ÷ °ü·Ã ÇÕº´Áõ µî ¼öÇ÷°ú °ü·ÃµÈ À§ÇèÀ» ÁÙ¿© ȯÀÚÀÇ ¾ÈÀüÀ» Çâ»ó½ÃŰ´Â ´É·Â¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ°Å ±â¹Ý Á¢±Ù¹ýÀº Ç÷¾×Á¦Á¦¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í Á¶±â ȸº¹À¸·Î À̾îÁö±â ¶§¹®¿¡ ¼ö¼ú, ¿Ü»ó, ¸¸¼º ºóÇ÷ ȯÀÚ¿¡°Ô ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

PBMÀº ºÒÇÊ¿äÇÑ ¼öÇ÷À» ÃÖ¼ÒÈ­ÇÔÀ¸·Î½á °¡¿ë·®ÀÌ Á¦ÇÑÀûÀÎ Ç÷¾× °ø±ÞÀ» Àý¾àÇÏ´Â µ¥¿¡µµ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº ƯÈ÷ Ç÷¾×ÀÌ ºÎÁ·Çϰųª Ç÷¾×Á¦Á¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑµÈ Áö¿ªÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡ ÇʼöÀûÀÔ´Ï´Ù. Àα¸ °í·ÉÈ­¿Í ¼ö¼ú Áõ°¡·Î ÀÎÇØ Ç÷¾×¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â °¡¿îµ¥, PBMÀº Ç÷¾×À» °¡Àå ÇÊ¿ä·Î Çϴ ȯÀÚ¿¡°Ô Ç÷¾×ÀÌ °ø±ÞµÉ ¼ö ÀÖµµ·Ï Çϸ鼭 È¿À²ÀûÀÎ Ç÷¾× »ç¿ëÀ» Àå·ÁÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °üÇàÀº ÀÚ¿øÀ» Àý¾àÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¼öÇ÷°ú °ü·ÃµÈ ÀÇ·á ºñ¿ëÀ» ³·Ãç PBMÀ» Áö¼Ó°¡´ÉÇÑ ÀÇ·á °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ¸¸µé°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ PBMÀº °¢ ȯÀÚÀÇ Ç÷¾× ¼ö¿ä¸¦ °ü¸®Çϱâ À§ÇØ ¿¹¹æÀûÀÌ°í °³º°È­µÈ Á¢±Ù ¹æ½ÄÀ» ÃëÇÔÀ¸·Î½á Àü¹ÝÀûÀÎ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. PBMÀº öºÐ º¸Ãæ, ÀûÇ÷±¸ Á¶Ç÷ ÃËÁøÁ¦, °í±Þ ¼ö¼ú ±â¹ý µîÀÇ °³ÀÔÀ» ÅëÇØ ¼ö¼úÀ̳ª Ä¡·á Àü¿¡ ȯÀÚ¸¦ ÃæºÐÈ÷ Áغñ½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ Á¾ÇÕÀûÀÎ Á¢±Ù ¹æ½ÄÀº ÇÕº´Áõ ¹ß»ý °¡´É¼ºÀ» ÁÙÀ̰í ÀÔ¿ø ±â°£À» ´ÜÃàÇϸç ȸº¹ ½Ã°£À» ¿¬ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á¿¡¼­ ȯÀÚ Áß½ÉÀÇ Ä¡·á°¡ Á¡Á¡ ´õ Áß¿ä½ÃµÇ´Â °¡¿îµ¥ PBMÀº Çö´ë ÀÇ·á Á¦°øÀÇ ¿øÄ¢¿¡ µû¶ó ¸ÂÃãÇü ¿¹¹æ Àü·«À» Á¦°øÇÏ¿© ȯÀÚ ¸¸Á·µµ¿Í °Ç°­ °á°ú¸¦ ¸ðµÎ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ȯÀÚÀÇ Ç÷¾× °ü¸®¸¦ °­È­Çϴ°¡?

±â¼úÀÇ ¹ßÀüÀº Ç÷¾× »ç¿ëÀ» ÃÖÀûÈ­Çϰí Ç÷¾× ¼Õ½ÇÀ» ÃÖ¼ÒÈ­Çϸç ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â »õ·Î¿î Åø¿Í ¹æ¹ýÀ» µµÀÔÇÔÀ¸·Î½á ȯÀÚ Ç÷¾× °ü¸®¸¦ Å©°Ô °³¼±Çϰí ÀÖ½À´Ï´Ù. POC(Point-of-Care) °Ë»ç ¹× ÀÚµ¿ Ç÷¾× ºÐ¼®±â¿Í °°Àº ±â¼úÀº ½Å¼ÓÇÑ Çì¸ð±Û·Îºó Æò°¡ ¹× öºÐ °áÇÌ Æò°¡¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ÀÇ·áÁøÀÌ ºóÇ÷À» Á¶±â¿¡ Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Á¤È®ÇÑ ½Ç½Ã°£ Áø´ÜÀ» ÅëÇØ ÀÓ»óÀÇ´Â Çì¸ð±Û·Îºó ¼öÄ¡¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ °³º°È­ Àü·«À» »çÀü¿¡ ½ÇÇàÇÏ¿© ¼öÇ÷ÀÌ ÇÊ¿äÇÒ °¡´É¼ºÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº PBMÀÇ ÇÙ½É ¿ä¼ÒÀÎ ¿¹¹æÀû ºóÇ÷ °ü¸®¸¦ Áö¿øÇÏ¿© ȯÀÚ°¡ Ä¡·á¸¦ ¹Þ±â Àü¿¡ ÃÖ»óÀÇ »óŸ¦ À¯ÁöÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù.

PBMÀÇ ¶Ç ´Ù¸¥ Å« ¹ßÀüÀº ¼ö¼ú Áß ÃâÇ÷À» ÃÖ¼ÒÈ­ÇÏ°í ¼öÇ÷ÀÇ Çʿ伺À» °¨¼Ò½ÃŰ´Â ¼¼Æ÷ ȸ¼ö ¹× Ç÷¾× º¸Á¸ ¼ö¼ú ±â¹ýÀÇ »ç¿ëÀÔ´Ï´Ù. ¼ö¼ú Áß ¼¼Æ÷±¸Ãâ Àåºñ´Â ¼ö¼ú Áß È¯ÀÚÀÇ Ç÷¾×À» ȸ¼ö ¹× ó¸®ÇÏ¿© ȯÀÚ¿¡°Ô ´Ù½Ã ÁÖÀÔÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© ±âÁõÀÚ Ç÷¾×¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Ò Ä§½À ¼ö¼ú°ú º¹°­°æ ¼ö¼úÀº Àý°³Ã¢ÀÌ ÀÛ¾Æ ÃâÇ÷ÀÌ Àû±â ¶§¹®¿¡ Á¡Á¡ ´õ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº Á¤Çü¿Ü°ú¼ö¼úÀ̳ª ½ÉÀå ¼ö¼ú°ú °°ÀÌ ÃâÇ÷ÀÌ ¸¹Àº ¼ö¼ú¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. PBMÀº ¼¼Æ÷ ȸ¼ö ¹× ÃÖ¼Ò Ä§½À ±â¼úÀ» µµÀÔÇÏ¿© ¿ÜºÎ Ç÷¾×ÀÇ Çʿ伺À» ÁÙÀ̰í, ¼ö¼ú °á°ú¸¦ °³¼±Çϸç, ÀÚ¿ø È¿À²¼ºÀ» Áö¿øÇÕ´Ï´Ù.

ÀûÇ÷±¸ Á¶Ç÷ÀÚ±ØÁ¦(ESA)¿Í öºÐ º¸ÃæÁ¦¿Í °°Àº ÀǾàǰ Çõ½Åµµ ÀûÇ÷±¸ »ý¼ºÀ» ÃËÁøÇÏ°í ¼öÇ÷ ¾øÀÌ ºóÇ÷À» Ä¡·áÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ESA´Â °ñ¼ö¸¦ ÀÚ±ØÇÏ¿© ´õ ¸¹Àº ÀûÇ÷±¸¸¦ »ý¼ºÇϵµ·Ï µµ¿ÍÁֱ⠶§¹®¿¡ ¸¸¼º ºóÇ÷ ȯÀÚ³ª È­Çпä¹ýÀ» ¹Þ´Â ȯÀÚ¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¸¸¼º ºóÇ÷ ȯÀÚ³ª È­Çпä¹ýÀ» ¹Þ´Â ȯÀÚ¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. öºÐ º¸ÃæÁ¦´Â °æ±¸ ¶Ç´Â Á¤¸Æ Áֻ縦 ÅëÇØ Çì¸ð±Û·ÎºóÀ» ÃÖÀûÈ­Çϰí ÃâÇ÷À» µ¿¹ÝÇÒ ¼ö ÀÖ´Â ½Ã¼ú¿¡ ´ëºñÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϸç, PBMÀº ¼öÇ÷ÀÇ Çʿ伺À» ÃÖ¼ÒÈ­Çϸ鼭 ȯÀÚÀÇ °Ç°­À» ÁõÁø½ÃŲ´Ù´Â ¸ñÇ¥¿¡ µû¶ó ÀÌ·¯ÇÑ ¾à¹° ÁßÀ縦 ÅëÇØ ºóÇ÷ °ü¸®¸¦ À§ÇÑ ºñ¼öÇ÷ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ÀÓ»óÀǰ¡ °¢ ȯÀÚÀÇ Çʿ信 µû¶ó PBM Àü·«À» Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Ç÷¾× °ü¸®¿¡ ´ëÇÑ º¸´Ù È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

ȯÀÚÀÇ Ç÷¾× °ü¸®´Â ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô ¾î¶² ÀÌÁ¡ÀÌ Àִ°¡?

ȯÀÚ Ç÷¾× °ü¸®´Â ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¸ðµÎ¿¡°Ô Å« ÀÌÁ¡À» Á¦°øÇÏ¿© ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÇ·á ºñ¿ëÀ» Àý°¨Çϸç Á¦ÇÑµÈ Ç÷¾× ÀÚ¿øÀÇ »ç¿ëÀ» ÃÖÀûÈ­ÇÕ´Ï´Ù. ȯÀÚÀÇ °æ¿ì, PBMÀº °¨¿°, ¼öÇ÷ ¹ÝÀÀ, ¸é¿ªÇÐÀû ÇÕº´Áõ°ú °°Àº ¼öÇ÷°ú °ü·ÃµÈ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ¿© ¾ÈÀü¼ºÀ» ³ôÀÔ´Ï´Ù. PBMÀº ºóÇ÷ °ü¸®, ¿Ü°úÀû º¸Á¸ ±â¼ú, ȯÀÚ ÀÚ½ÅÀÇ Ç÷¾× »ç¿ë µî ¼öÇ÷ ÀÌ¿ÜÀÇ °³ÀÔÀ» ÅëÇØ ºÎÀÛ¿ëÀÇ °¡´É¼ºÀ» ÁÙÀÌ°í º¸´Ù ¾ÈÀüÇÑ ÀÇ·á ¼­ºñ½º¸¦ ÃËÁøÇÕ´Ï´Ù. ´ë¼ö¼úÀ» ¹Þ´Â ȯÀÚÀÇ °æ¿ì, PBMÀº ȯÀÚÀÇ °Ç°­À» ¿ì¼±½ÃÇÏ°í ¼öÇ÷ÀÇ Çʿ伺À» ÁÙ¿© ȸº¹ ½Ã°£À» ´ÜÃàÇϰí ÀÔ¿ø ±â°£À» ´ÜÃàÇÒ ¼ö ÀÖµµ·Ï ¼¼½ÉÇÏ°Ô °ü¸®µÇ´Â Ç÷¾× Àü·«À» º¸ÀåÇÕ´Ï´Ù.

PBMÀº ÀÇ·á±â°üÀÇ °æ¿ì, °ø±ÞÀÌ Á¦ÇÑÀûÀÎ ÇåÇ÷ÀÚ Ç÷¾×¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãç È¿À²ÀûÀ̰í Áö¼Ó°¡´ÉÇÑ ÀÚ¿ø °ü¸®¸¦ µ½½À´Ï´Ù. ÇåÇ÷·üÀÌ ¼ö¿ä Áõ°¡¸¦ µû¶óÀâÁö ¸øÇÏ´Â »óȲ¿¡¼­ PBMÀº ¿Ü»óÀ̳ª ÁßÁõ ÃâÇ÷ ȯÀÚ µî Áß¿äÇÑ Çʿ䰡 Àִ ȯÀÚµéÀ» À§ÇØ Ç÷¾× ÀÚ¿øÀ» È®º¸ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÃÖÀûÈ­µÈ Ä¡·á¿Í ¼öÇ÷ ÀÌ¿ÜÀÇ °³ÀÔÀ» ÅëÇØ Ç÷¾× »ç¿ë·®À» ÁÙÀÓÀ¸·Î½á ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ÀÚ¿øÀ»º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÏ¿© Ç÷¾× ºÎÁ· À§ÇèÀ» ³·Ãß°í ½ÇÁ¦·Î ÇÊ¿äÇÒ ¶§ Ç÷¾× Á¦Á¦¸¦ »ç¿ëÇÒ ¼ö ÀÖµµ·ÏÇÕ´Ï´Ù, ¼öÇ÷°ú °ü·ÃµÈ ºñ¿ëÀ» Àý°¨ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ë È¿À²¼ºÀº Ç÷¾× ÀÚ¿øÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÔÀ¸·Î½á »ó´çÇÑ ÀçÁ¤Àû Àý°¨À¸·Î À̾îÁö´Â ´ë±Ô¸ð º´¿ø ¹× ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ƯÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù.

PBMÀÇ ¶Ç ´Ù¸¥ ÀåÁ¡Àº ȯÀÚ °á°ú¿Í Ä¡·áÀÇ ÁúÀ» Çâ»ó½ÃÄÑ È¯ÀÚ Áß½ÉÀÇ °³º°È­µÈ ÀÇ·á Á¢±ÙÀ» ÃËÁøÇÏ´Â °ÍÀÔ´Ï´Ù. PBMÀº ºóÇ÷ Á¶±â ¹ß°ß, Ç÷¾×À» Àý¾àÇÏ´Â ¼ö¼ú, ¼öÇ÷À» ÇÏÁö ¾Ê´Â ¼±Åà µîÀ» ÅëÇØ ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ°¡ °¢ ȯÀÚÀÇ Çʿ信 ¸Â´Â ¸ÂÃã Ä¡·á °èȹÀ» ¼¼¿ï ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ¸ÂÃãÇü Á¢±Ù ¹æ½ÄÀº ÇÕº´Áõ ¹ß»ý °¡´É¼ºÀ» ÁÙÀ̰í, ºü¸¥ ȸº¹À» Áö¿øÇϸç, ȯÀÚ ¸¸Á·µµ¿Í Àü¹ÝÀûÀÎ Ä¡·áÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ȯÀÚÀÇ Ç÷¾× °Ç°­ »óŸ¦ Àû±ØÀûÀ¸·Î °ü¸®ÇÔÀ¸·Î½á PBMÀº ÀÔ¿ø ¹× ÀçÀÔ¿øÀ» ÃÖ¼ÒÈ­ÇÏ°í º¸´Ù ÇÕ¸®ÀûÀÎ ÀÇ·á °æÇèÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡Àº ÀÇ·á ¼­ºñ½º Á¦°øÀÇ ÀÓ»óÀû Ãø¸é°ú ¿î¿µÀû Ãø¸éÀ» ¸ðµÎ °³¼±ÇÏ¿© ¾çÁúÀÇ, ºñ¿ë È¿À²ÀûÀ̸ç ȯÀÚ Áß½ÉÀÇ Ä¡·á¶ó´Â ¸ñÇ¥¸¦ Áö¿øÇÕ´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¼öÇ÷ °ü·Ã À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼ö¼ú ¹× ¸¸¼ºÁúȯ »ç·Ê Áõ°¡, Áø´Ü ¹× Ä¡·á ±â¼ú ¹ßÀü, PBM µµÀÔÀ» ÃËÁøÇÏ´Â ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø Á¤Ã¥ µîÀÌ ÀÖ½À´Ï´Ù. ¼öÇ÷°ú °ü·ÃµÈ À§Çè°ú ÇÕº´Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ±âÁ¸ÀÇ ¼öÇ÷ ¹æ¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ¹æ¹ýÀ» ã°í ÀÖ½À´Ï´Ù. °¨¿°, ¸é¿ªÇÐÀû ¹ÝÀÀ, ÀáÀçÀû ÇÕº´Áõ¿¡ ´ëÇÑ ¿ì·Á´Â ¼öÇ÷À» ÃÖ¼ÒÈ­ÇÏ°í º¸´Ù ¾ÈÀüÇÑ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ´Â PBM ÇÁ·Î±×·¥ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»óÀû °üÁ¡ÀÇ º¯È­·Î ÀÎÇØ ´õ ¸¹Àº º´¿ø°ú ÀÇ·á ±â°üÀÌ PBM ÇÁ·ÎÅäÄÝÀ» äÅÃÇϰí ÀÖÀ¸¸ç, Á¾ÇÕÀûÀÎ Ç÷¾× °ü¸®¸¦ Áö¿øÇÏ´Â ±â¼ú°ú ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼ö¼ú °Ç¼ö Áõ°¡¿Í ¾Ï, ½ÅÀåÁúȯ, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡µµ PBM ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ¼ö¼úÀ̳ª ÀæÀº ÀÔ¿øÀ» ÇÊ¿ä·Î ÇÏ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ÀÇ·áÁøÀº ¼öÇ÷¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀ̸鼭 ȯÀÚ Ä¡·á¸¦ Áö¿øÇÏ´Â È¿°úÀûÀÎ Ç÷¾× °ü¸® Àü·«ÀÌ ÇÊ¿äÇϸç, PBM ÇÁ·ÎÅäÄÝÀº ¼ö¼ú Àü°ú ¼ö¼ú Áß È¯ÀÚÀÇ Ç÷¾× »óŸ¦ ÃÖÀûÈ­ÇÏ¿© ¼öÇ÷ÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. ¼öÇ÷ÀÇ Çʿ伺À» ÁÙÀÏ ¼ö ÀÖÀ¸¹Ç·Î ÃâÇ÷ÀÌ ¸¹Àº ¼ö¼ú¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¼ö¼ú ¹× ÀÔ¿ø °Ç¼ö°¡ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó Ç÷¾×À» È¿À²ÀûÀ¸·Î °ü¸®Çϰí ȯÀÚ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇÑ È¿°úÀûÀÎ PBM ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿äµµ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áø´Ü ¹× Ä¡·á ±â¼úÀÇ ¹ßÀüÀº º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ ¸ÂÃãÇü Ç÷¾× °ü¸® Àü·«À» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á PBM ½ÃÀåÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇöÀå °Ë»ç ¹× °í±Þ ºóÇ÷ ¼±º°°Ë»ç¿Í °°Àº »õ·Î¿î Áø´Ü ÅøÀº ȯÀÚÀÇ Ç÷¾× ¼öÄ¡¸¦ Á¶±â¿¡ °³ÀÔÇϰí Á¤È®ÇÏ°Ô °ü¸®ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¼¼Æ÷ ±¸Á¦ Àåºñ¿Í ÃÖ¼Òħ½ÀÀû ¼ö¼ú¹ýÀ» Æ÷ÇÔÇÑ ¿Ü°úÀû Çõ½ÅÀº ¼ö¼ú Áß Ç÷¾× ¼Õ½ÇÀ» ÁÙÀÌ°í °ø¿© Ç÷¾×ÀÇ Çʿ伺À» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ÀûÇ÷±¸ Á¶Ç÷ ÃËÁøÁ¦ ¹× Á¤¸Æ³» öºÐ º¸ÃæÁ¦ µî ÀǾàǰÀÇ ¹ßÀüÀº ºóÇ÷ ȯÀÚ¿¡°Ô ¼öÇ÷ ÀÌ¿ÜÀÇ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº PBM ÇÁ·Î±×·¥À» º¸´Ù ½±°í È¿°úÀûÀ¸·Î ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô ÇØÁÖ°í, Àü ¼¼°è º´¿ø°ú ÀÇ·á ½Ã¼³¿¡¼­ PBM ÇÁ·Î±×·¥ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·á ±â°ü°ú Á¤ºÎ°¡ ȯÀÚ ¾ÈÀüÀ» °³¼±Çϰí Ç÷¾× ÀÚ¿øÀ» ÃÖÀûÈ­ÇÏ´Â µ¥ ÀÖÀ¸¸ç, PBMÀÇ °¡Ä¡¸¦ ÀνÄÇÔ¿¡ µû¶ó PBM ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇÏ´Â ±ÔÁ¦ Á¤Ã¥°ú °¡À̵å¶óÀεµ PBM ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿Í °°Àº ±ÔÁ¦±â°ü°ú ¿©·¯ ±¹°¡ÀÇ º¸°ÇºÎ´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Ç¥ÁØ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ÀϺηΠPBMÀ» äÅÃÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ÀÇ·á ½Ã½ºÅÛÀº ǰÁú Ç¥ÁØÀ» ÁؼöÇϰí ÀÇ·á ºñ¿ëÀ» Àý°¨Çϸç Ç÷¾× ÀÚ¿øÀ» Àý¾àÇϱâ À§ÇØ º´¿ø¿¡ PBM Àü·«À» ½ÃÇàÇϵµ·Ï ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ ¿ËÈ£ ´Üü¿Í ÀÇ·á ±â°üÀº ÀÇ·á Á¾»çÀÚ¿Í ÀÏ¹Ý ´ëÁß¿¡°Ô PBMÀÇ ÀÌÁ¡À» ¾Ë¸®±â À§ÇØ ±³À° Ȱµ¿À» °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦¿Í ¿ËÈ£ ³ë·ÂÀº PBMÀÇ Ã¤ÅÃÀ» È®´ëÇϰí ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ º£½ºÆ® ÇÁ·¢Æ¼½º¿Í ÄÄÇöóÀ̾𽺠ǥÁØÀ» ÁؼöÇÔ¿¡ µû¶ó ½ÃÀåÀÇ Å« ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¼öÇ÷ À§Çè¿¡ ´ëÇÑ ÀνÄ, ¼ö¼ú ¹× ¸¸¼ºÁúȯ Áõ°¡, ±â¼ú ¹ßÀü, Áö¿øÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© µî ´Ù¾çÇÑ ¿äÀÎÀÌ °áÇյǾî ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ º¸´Ù ¾ÈÀüÇÏ°í ºñ¿ë È¿À²ÀûÀ̸ç ÀÚ¿ø È¿À²ÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ´Â °¡¿îµ¥, PBMÀº ȯÀÚ Áß½ÉÀÇ Çö´ëÀû ÀÇ·á ¼­ºñ½º Á¦°øÀÇ Ãʼ®ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(Àåºñ, ½Ã¾à & ŰƮ, ¼ÒÇÁÆ®¿þ¾î, ¾×¼¼¼­¸®);¼ººÐ(ÀüÇ÷ & ÀûÇ÷±¸, Ç÷Àå);ÃÖÁ¾ »ç¿ë(Ç÷¾×ÀºÇà, º´¿ø)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 42»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Patient Blood Management Market to Reach US$23.6 Billion by 2030

The global market for Patient Blood Management estimated at US$15.2 Billion in the year 2023, is expected to reach US$23.6 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$10.1 Billion by the end of the analysis period. Growth in the Reagents & Kits segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 9.8% CAGR

The Patient Blood Management market in the U.S. is estimated at US$4.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Patient Blood Management Market - Key Trends & Drivers Summarized

Why Is Patient Blood Management Essential in Modern Healthcare?

Patient Blood Management (PBM) has become a crucial component in modern healthcare, providing a systematic approach to optimize the care of patients who might need blood transfusions. PBM focuses on minimizing the need for blood transfusions by managing anemia, reducing blood loss during surgery, and optimizing patients' red blood cell mass, thereby improving clinical outcomes. The importance of PBM lies in its ability to enhance patient safety by reducing the risks associated with transfusions, such as infections, immune reactions, and transfusion-related complications. This evidence-based approach is especially important for patients undergoing surgeries, trauma cases, or those with chronic anemia, as it reduces dependency on blood products and leads to faster recovery.

By minimizing unnecessary transfusions, PBM also plays a significant role in conserving blood supplies, which are often in limited availability. This approach is vital for healthcare systems, particularly in times of blood shortages or in regions with limited access to blood products. With the rising demand for blood due to aging populations and increasing surgical procedures, PBM ensures that blood is available for patients who need it most while encouraging efficient blood use. This practice not only conserves resources but also lowers healthcare costs associated with blood transfusions, making PBM essential for sustainable healthcare management.

Moreover, PBM promotes better overall outcomes by taking a preventive, individualized approach to managing each patient's blood needs. Through interventions like iron supplementation, erythropoiesis-stimulating agents, and advanced surgical techniques, PBM prepares patients adequately before surgery or treatment. This comprehensive approach reduces the likelihood of complications, shortens hospital stays, and enhances recovery times. As healthcare increasingly emphasizes patient-centered care, PBM provides a tailored, preventive strategy that aligns with modern principles of healthcare delivery, improving both patient satisfaction and health outcomes.

How Are Technological Advancements Enhancing Patient Blood Management?

Technological advancements are significantly enhancing Patient Blood Management by introducing new tools and methods that optimize blood use, minimize blood loss, and improve patient outcomes. One key innovation in PBM is the development of advanced diagnostic tools that allow for early detection and management of anemia before surgery or treatment. Technologies like point-of-care (POC) testing and automated blood analyzers enable rapid hemoglobin assessments and iron deficiency evaluations, allowing healthcare providers to diagnose and treat anemia early. With accurate, real-time diagnostics, clinicians can implement personalized strategies to optimize hemoglobin levels in advance, reducing the likelihood of needing transfusions. These technologies support proactive anemia management, a core component of PBM, ensuring that patients are in the best possible condition before undergoing procedures.

Another major advancement in PBM is the use of cell salvage and blood-sparing surgical techniques, which minimize blood loss and reduce transfusion needs during surgery. Intraoperative cell salvage devices collect and process a patient’s blood during surgery, allowing it to be reinfused back into the patient, thus reducing dependency on donor blood. Additionally, minimally invasive and laparoscopic surgical techniques are becoming increasingly common, as they involve smaller incisions, leading to less blood loss. These techniques are particularly beneficial in high-blood-loss surgeries, such as orthopedic and cardiac procedures. By incorporating cell salvage and minimally invasive techniques, PBM reduces the need for external blood, improving surgical outcomes and supporting resource efficiency.

Pharmaceutical innovations, such as erythropoiesis-stimulating agents (ESAs) and iron supplements, are also playing a critical role in PBM by boosting red blood cell production and addressing anemia without the need for transfusions. ESAs stimulate the bone marrow to produce more red blood cells, which is especially beneficial for patients with chronic anemia or those undergoing chemotherapy. Iron supplements, whether oral or intravenous, support hemoglobin optimization, preparing patients for procedures that may involve blood loss. With these pharmaceutical interventions, PBM offers non-transfusion options for managing anemia, aligning with its goal to enhance patient health while minimizing transfusion requirements. These therapies empower clinicians to tailor PBM strategies to each patient’s needs, providing a more effective and less invasive approach to blood management.

What Are the Benefits of Patient Blood Management for Patients and Healthcare Providers?

Patient Blood Management provides significant benefits for both patients and healthcare providers, improving patient outcomes, reducing healthcare costs, and optimizing the use of limited blood supplies. For patients, PBM enhances safety by minimizing the risks associated with blood transfusions, such as infections, transfusion reactions, and immunologic complications. By employing non-transfusion interventions like anemia management, surgical blood-sparing techniques, and the use of patient’s own blood, PBM reduces the potential for adverse reactions and promotes a safer healthcare experience. For patients undergoing major surgeries, PBM offers the assurance of a carefully managed blood strategy that prioritizes their health, reduces the need for transfusions, and leads to quicker recovery times and shorter hospital stays.

For healthcare providers, PBM supports efficient and sustainable resource management by reducing reliance on donor blood, which is often in limited supply. With blood donation rates unable to keep pace with increasing demand, PBM helps preserve blood resources for patients with critical needs, such as trauma or severe bleeding cases. By reducing blood usage through optimized care and non-transfusion interventions, healthcare providers can manage resources more effectively, lowering the risk of blood shortages and ensuring that blood products are available when truly necessary. PBM also decreases costs associated with blood transfusions, including storage, screening, and administration expenses. This cost-efficiency is especially valuable in large hospitals and health systems, where managing blood resources effectively can lead to substantial financial savings.

Enhanced patient outcomes and quality of care are additional benefits of PBM, as it fosters a more patient-centered, individualized approach to healthcare. Through early anemia detection, blood-sparing surgical practices, and non-transfusion options, PBM enables healthcare providers to create personalized care plans tailored to each patient’s needs. This customized approach reduces the likelihood of complications and supports faster recoveries, improving patient satisfaction and overall quality of care. By proactively managing patients’ blood health, PBM minimizes hospital stays and readmissions, leading to a more streamlined healthcare experience. Together, these benefits improve both the clinical and operational aspects of healthcare delivery, supporting the goal of high-quality, cost-effective, and patient-centered care.

What Is Fueling the Growth in the Patient Blood Management Market?

The growth in the Patient Blood Management market is driven by the rising awareness of transfusion-related risks, increasing surgical and chronic disease cases, advancements in diagnostic and therapeutic technologies, and supportive regulatory policies promoting PBM adoption. As awareness grows around the risks and complications associated with blood transfusions, healthcare providers are increasingly seeking safer and more effective alternatives to traditional transfusion practices. Concerns over infections, immunologic reactions, and potential complications have highlighted the need for PBM programs that minimize transfusions and provide safer care options. This shift in clinical perspective has encouraged more hospitals and healthcare facilities to adopt PBM protocols, driving demand for technologies and practices that support comprehensive blood management.

Increasing numbers of surgeries and the rising prevalence of chronic diseases, such as cancer, kidney disease, and cardiovascular conditions, are also fueling the demand for PBM solutions. With these conditions often requiring surgical interventions or frequent hospitalizations, healthcare providers need effective blood management strategies to support patient care while reducing transfusion dependency. PBM protocols are particularly valuable in high-blood-loss surgeries, as they optimize patient blood health before and during procedures, decreasing the need for transfusions. As the volume of surgeries and hospitalizations continues to grow, so does the demand for effective PBM solutions to manage blood efficiently and improve patient outcomes.

Advancements in diagnostic and therapeutic technologies are significantly contributing to PBM market growth, as they enable more precise, effective, and personalized blood management strategies. New diagnostic tools, such as point-of-care testing and advanced anemia screening, allow for early intervention and accurate management of patient blood levels. Surgical innovations, including cell salvage devices and minimally invasive techniques, reduce blood loss during procedures, minimizing the need for donor blood. Pharmaceutical advancements, such as erythropoiesis-stimulating agents and intravenous iron supplements, provide non-transfusion treatment options for patients with anemia. These technological innovations make PBM programs more accessible and effective, supporting their adoption in hospitals and healthcare facilities worldwide.

Supportive regulatory policies and guidelines are also driving growth in the PBM market, as healthcare organizations and governments recognize the value of PBM in improving patient safety and optimizing blood resources. Regulatory bodies like the World Health Organization (WHO) and health ministries in several countries are encouraging healthcare providers to adopt PBM practices as part of their standard care protocols. Many healthcare systems now require hospitals to implement PBM strategies to comply with quality standards, reduce healthcare costs, and conserve blood resources. Additionally, patient advocacy groups and health organizations have increased educational efforts to promote awareness of PBM benefits among healthcare professionals and the public. These regulatory and advocacy efforts are expanding the adoption of PBM, driving significant growth in the market as providers align with best practices and compliance standards.

Together, these factors—awareness of transfusion risks, increasing surgical and chronic disease prevalence, technological advancements, and supportive regulatory frameworks—are driving robust growth in the Patient Blood Management market. As healthcare systems aim to provide safer, more cost-effective, and resource-efficient care, PBM is becoming a cornerstone of modern, patient-centered healthcare delivery.

SCOPE OF STUDY:

The report analyzes the Patient Blood Management market in terms of US$ Million by the following Component; End-Use; Product, and Geographic Regions/Countries:

Segments:

Product (Instruments, Reagents & Kits, Software, Accessories); Component (Whole Blood & Red Blood Cells, Plasma); End-Use (Blood Banks, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â